Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Notes Payables: 2009-2024

Historic Notes Payables for Northwest Biotherapeutics (NWBO) over the last 16 years, with Dec 2024 value amounting to $14.2 million.

  • Northwest Biotherapeutics' Notes Payables rose 79.09% to $13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.6 million, marking a year-over-year increase of 79.09%. This contributed to the annual value of $14.2 million for FY2024, which is 259.69% up from last year.
  • Per Northwest Biotherapeutics' latest filing, its Notes Payables stood at $14.2 million for FY2024, which was up 259.69% from $3.9 million recorded in FY2023.
  • Northwest Biotherapeutics' 5-year Notes Payables high stood at $15.4 million for FY2022, and its period low was $2.4 million during FY2020.
  • Moreover, its 3-year median value for Notes Payables was $14.2 million (2024), whereas its average is $11.2 million.
  • In the last 5 years, Northwest Biotherapeutics' Notes Payables tumbled by 74.39% in 2023 and then soared by 259.69% in 2024.
  • Yearly analysis of 5 years shows Northwest Biotherapeutics' Notes Payables stood at $2.4 million in 2020, then spiked by 191.51% to $7.1 million in 2021, then surged by 116.82% to $15.4 million in 2022, then crashed by 74.39% to $3.9 million in 2023, then spiked by 259.69% to $14.2 million in 2024.